Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were initially developed for the treatment of diabetes due to their antihyperglycemic activity. However, in the light of the most recent clinical studies, they are revolutionizing the approach to cardiovascular disease in patients with and without d...

Descripción completa

Detalles Bibliográficos
Autores principales: Cesaro, Arturo, Acerbo, Vincenzo, Vetrano, Erica, Signore, Giovanni, Scherillo, Gianmaria, Rotolo, Francesco Paolo, De Michele, Gianantonio, Scialla, Francesco, Raucci, Giuseppe, Panico, Domenico, Gragnano, Felice, Moscarella, Elisabetta, Galiero, Raffaele, Caturano, Alfredo, Ruggiero, Roberto, Sasso, Ferdinando Carlo, Calabrò, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179032/
https://www.ncbi.nlm.nih.gov/pubmed/37175805
http://dx.doi.org/10.3390/ijms24098099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179032/
https://www.ncbi.nlm.nih.gov/pubmed/37175805
http://dx.doi.org/10.3390/ijms24098099

Ejemplares similares